<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02801435</url>
  </required_header>
  <id_info>
    <org_study_id>BD-ICC-I01</org_study_id>
    <nct_id>NCT02801435</nct_id>
  </id_info>
  <brief_title>Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis</brief_title>
  <official_title>A Single-Center, Randomized, Double-blind, Placebo-Controlled Study to Evaluate Safety, Tolerability and Pharmacokinetics of Icotinib Hydrochloride Cream in Patients With Mild to Moderate Psoriasis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Betta Pharmaceuticals Co., Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Tigermed Consulting Co., Ltd</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Betta Pharmaceuticals Co., Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is a phase I study to evaluate the safety, tolerability and pharmacokinetics of Icotinib&#xD;
      Hydrochloride Cream in patients with mild to moderate psoriasis.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Icotinib Hydrochloride is a small-molecule epidermal growth factor receptor (EGFR) tyrosine&#xD;
      kinase inhibitor, which has been approved for the treatment of advanced nonsmall- cell lung&#xD;
      cancer (NSCLC) in China in its oral form. As EGFR is implicated in the pathogenesis of&#xD;
      psoriasis, icotinib hydrochloride is being developed as a cream for the treatment of mild to&#xD;
      moderate psoriasis. This is a single-center, randomized, doubleblind, placebo-controlled&#xD;
      study of 0.5%, 1.0%, 2.0%, 4.0% icotinib hydrochloride cream by topical administration.&#xD;
      Icotinib hydrochloride cream will be applied to subjects with mild to moderate psoriasis.&#xD;
      Approximately 40 subjects will be enrolled.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">September 17, 2016</start_date>
  <completion_date type="Actual">June 8, 2017</completion_date>
  <primary_completion_date type="Actual">June 8, 2017</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety in patients with mild to moderate psoriasis</measure>
    <time_frame>28 days</time_frame>
    <description>Incidence and severity of Adverse Events (AE), Physical Examinations, Vital signs (temperature, Heart Rate (HR), BP and respiration); Clinical laboratory assessments (serum chemistry, hematology, C-reactive protein , fecal and urinalysis); ECG;</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Tolerance-related skin reactions in patients with mild to moderate psoriasis at the treatment site</measure>
    <time_frame>28 days</time_frame>
    <description>Skin irritation and allergy observation (including redness, swelling,rash, itching, pain) recorded by grades</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Lesion severity</measure>
    <time_frame>28 days</time_frame>
    <description>Erythema , scale , thickness of target site on patients with mild to moderate psoriasis</description>
  </other_outcome>
  <other_outcome>
    <measure>Lesion area</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Psoriasis Area and Severity Index (PASI) Scores in patients with mild to moderate psoriasis</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Physician's Global Assessment(PGA) in patients with mild to moderate psoriasis</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Dermatology Life Quality Index (DLQI) in patients with mild to moderate psoriasis</measure>
    <time_frame>28 days</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time maximum concentration observed(tmax) of single-dose Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Peak plasma concentration (Cmax) of single-dose Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC) of single-dose Icotinib Hydrochloride Cream from zero(0) hours to time (t) in patients with mild to moderate psoriasis</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC) of single-dose Icotinib Hydrochloride Cream from zero (0) hours to infinity (∞) in patients with mild to moderate psoriasis</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half life(t1/2) of single-dose Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis</measure>
    <time_frame>12 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Time maximum concentration observed(tmax) of repeat-dose Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Stable peak plasma concentration (Cmaxss) of repeat-dose Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC) of repeat-dose Icotinib Hydrochloride Cream from zero(0) hours to time (t) in patients with mild to moderate psoriasis</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Area under the plasma concentration versus time curve(AUC) of repeat-dose Icotinib Hydrochloride Cream from zero (0) hours to infinity (∞) in patients with mild to moderate psoriasis</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <other_outcome>
    <measure>Half life(t1/2) of repeat-dose Icotinib Hydrochloride Cream in patients with mild to moderate psoriasis</measure>
    <time_frame>24 hours</time_frame>
  </other_outcome>
  <number_of_arms>8</number_of_arms>
  <enrollment type="Actual">41</enrollment>
  <condition>Psoriasis</condition>
  <arm_group>
    <arm_group_label>Cohort 1-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients with mild to moderate psoriasis will be randomized to receive 0.5% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 1-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients with mild to moderate psoriasis will be randomized to receive 1.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 2-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients with mild to moderate psoriasis will be randomized to receive 2.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 3-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4-Experimental</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>8 patients with mild to moderate psoriasis will be randomized to receive 4.0% Icotinib hydrochloride cream, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cohort 4-Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>2 patients with mild to moderate psoriasis will be randomized to receive matching placebo, applied twice daily for 4 consecutive weeks. The drug will be applied topically to the psoriasis site.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>0.5% Icotinib hydrochloride cream</intervention_name>
    <description>Topical administration for twice daily</description>
    <arm_group_label>Cohort 1-Experimental</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>1.0% Icotinib hydrochloride cream</intervention_name>
    <description>Topical administration for twice daily</description>
    <arm_group_label>Cohort 2-Experimental</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>2.0% Icotinib hydrochloride cream</intervention_name>
    <description>Topical administration for twice daily</description>
    <arm_group_label>Cohort 3-Experimental</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>4.0% Icotinib hydrochloride cream</intervention_name>
    <description>Topical administration for twice daily</description>
    <arm_group_label>Cohort 4-Experimental</arm_group_label>
    <other_name>no other name</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Topical administration for twice daily</description>
    <arm_group_label>Cohort 1-Placebo</arm_group_label>
    <arm_group_label>Cohort 2-Placebo</arm_group_label>
    <arm_group_label>Cohort 3-Placebo</arm_group_label>
    <arm_group_label>Cohort 4-Placebo</arm_group_label>
    <other_name>Blank cream</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Clinical diagnosis of plaque psoriasis for at least six months with multiple treatable&#xD;
             area (i.e. the lesion should not only on the face, scalp, genitals or skinfolds) of&#xD;
             plaque psoriasis covering less than 10% of the total Body Surface Area (BSA), affected&#xD;
             area on the limb and/or trunk≥ 1% BSA. A Target Plaque Area (TPA)≥9 cm2, with a Target&#xD;
             Plaque Severity Score(TPSS)≥ 5, and induration subscore≥2.&#xD;
&#xD;
          -  Male participants should be ≥ 50 kg, female participants should be ≥ 45 kg; BMI should&#xD;
             be between 19 and 28 kg/m2 (inclusive)&#xD;
&#xD;
          -  In good health, with no history of diseases of major organs and no abnormality found&#xD;
             on physical examination and vital signs&#xD;
&#xD;
          -  Non-allergic, with no known history of drug allergy&#xD;
&#xD;
          -  Men and women of childbearing potential must agree to use a contraceptive regimen&#xD;
             agreed by the doctor during the trial. Female subjects that are on hormonal&#xD;
             contraceptives must continue using the same hormonal contraceptive as that was used in&#xD;
             the past 3 months, with the same route of administration and the same dose during the&#xD;
             study&#xD;
&#xD;
          -  Have signed a written informed consent before entering the study&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Psoriasis guttata, psoriasis punctata, erythrodermic psoriasis, pustular psoriasis,&#xD;
             psoriasis arthritis&#xD;
&#xD;
          -  Any dermatological disease that might interfere psoriasis clinical evaluation or bring&#xD;
             the subject in danger, or have other serious dermatological disease other than&#xD;
             psoriasis.&#xD;
&#xD;
          -  Have received underlying treatments before entering the trial:&#xD;
&#xD;
        Topical anti-psoriasis treatment in 2 weeks, e.g. corticosteroids, retinoids acid,&#xD;
        anthranol, tars, keratolytics. Vitamin D analogues or local immune regulator treatment in 4&#xD;
        weeks; Emollient or cosmetics in 24 hours; Any psoriasis vaccine, or have participated in&#xD;
        any psoriasis vaccine trial; Biologics treatment in 12 weeks, e.g. Alefacept, Etanercept,&#xD;
        Infliximab, Adalimumab, Ustekinumab, Efalizumab; Any phototherapy or systemic treatment in&#xD;
        4 weeks, e.g. corticosteroids, methotrexate, retinoids acids, ciclosporin; Long time&#xD;
        exposure to natural light or artificial UV, or will have such exposure; Use of drug known&#xD;
        to harm certain organ in 12 weeks; Participated in any clinical trial in 4 weeks, or have&#xD;
        plan to participate any trial during treatment period;&#xD;
&#xD;
          -  Any clinically significant central nervous, cardiac, hepatic, renal, gastrointestinal,&#xD;
             respiratory, metabolic or musculoskeletal system disease history, or other&#xD;
             pathological/physiological condition that might disrupt the trial result&#xD;
&#xD;
          -  Alanine transaminase(ALT), aspartate aminotransferase (AST), total bilirubin&gt;1.5 Upper&#xD;
             Limit Normal (ULN), creatinine&gt;ULN&#xD;
&#xD;
          -  History of postural hypotension, or allergic diseases (asthma, urticaria, atopic&#xD;
             dermatitis or rhinitis)&#xD;
&#xD;
          -  Pulmonary disease demonstrated by chest X-ray examination&#xD;
&#xD;
          -  Physically or mentally disabled&#xD;
&#xD;
          -  Positive for Hepatitis B Surface Antigen (HBsAg), hepatitis C or anti-HIV test&#xD;
&#xD;
          -  Know allergic to active ingredient or excipient of the investigational product&#xD;
&#xD;
          -  Excessive smoker(&gt;10 cigarettes per day), or excessive alcohol intake (&gt;15g absolute&#xD;
             alcohol per day, equal to 450ml beer, 150ml wine or 50ml low-alcohol Chinese liquor)&#xD;
&#xD;
          -  Excessive drinking of tea, coffee or caffein-containing beverage (&gt;8 glasses per day)&#xD;
&#xD;
          -  Drug abuser&#xD;
&#xD;
          -  Poor compliance&#xD;
&#xD;
          -  Under gestation or lactation period&#xD;
&#xD;
          -  Other subject that in the investigator's opinion unsuitable to be enrolled&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Min Zheng</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU)</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Zourong Ruan</last_name>
    <role>Principal Investigator</role>
    <affiliation>The Second Affiliated Hospital of Zhejiang University School of Medicine (SAHZU)</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>The Second Affiliated hospital of Zhejiang University School of Medicine</name>
      <address>
        <city>Hangzhou</city>
        <state>Zhejiang</state>
        <zip>310009</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>July 2017</verification_date>
  <study_first_submitted>June 11, 2016</study_first_submitted>
  <study_first_submitted_qc>June 11, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 15, 2016</study_first_posted>
  <last_update_submitted>July 12, 2017</last_update_submitted>
  <last_update_submitted_qc>July 12, 2017</last_update_submitted_qc>
  <last_update_posted type="Actual">July 17, 2017</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EGFR inhibitor</keyword>
  <keyword>topical agent</keyword>
  <keyword>psoriasis</keyword>
  <keyword>phase 1</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Psoriasis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

